Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of androgen-independent prostate cancer~  * Evidence of rising PSA level (with or without new lesion by radiograph or physical examination), defined as follows:~    * PSA level \> 5 ng/mL and clearly rising on 2 measurements taken ≥ 2 weeks apart after androgen deprivation therapy (i.e., orchiectomy or luteinizing hormone-releasing hormone \[LHRH\] analogue) and antiandrogen withdrawal, if appropriate~ * PSA rising before and on the first value taken at 4 or 6 weeks after antiandrogen cessation is considered disease progression~* Measurable or evaluable disease as defined by any of the following:~  * Measurable or evaluable tumor masses by radiograph or physical examination~ * Evaluable PSA~* Concurrent LHRH analogue or diethylstilbestrol (DES) for testicular androgen suppression required if no prior bilateral orchiectomy~  * Patients receiving other monotherapy for testicular androgen suppression must switch to a LHRH analogue or DES ≥ 14 days prior to study entry~PATIENT CHARACTERISTICS:~* ECOG 0-2~* Life expectancy ≥ 12 weeks~* ANC ≥ 1,000/mm³~* Platelet count ≥ 75,000/mm³~* Hemoglobin \> 8.9 g/dL (transfusion or erythropoietin support allowed)~* Serum creatinine ≤ 1.8 mg/dL~* AST ≤ 4 times upper limit of normal (ULN)~* Total bilirubin ≤ 2.0 mg/dL~* Serum corrected calcium \< ULN~* No history of nephrolithiasis within the past 5 years~* No unstable, uncontrolled peptic ulcer disease, congestive heart failure, glaucoma, HIV, or diabetes~PRIOR CONCURRENT THERAPY:~* At least 28 days since prior androgen deprivation therapy (≥ 42 days for bicalutamide)~  * A 28-day washout period is not required for patients who have previously progressed despite antiandrogen withdrawal and who have resumed antiandrogens without reduction of PSA~* At least 14 days since prior radiotherapy~* At least 28 days since prior strontium 89~* At least 28 days since prior chemotherapy and/or investigational agents~* No concurrent medications or supplements that contain additional calcium (e.g., Tums)~* No concurrent radiotherapy for pain control or any other indication~* Concurrent bisphosphonates allowed provided dose/regimen is stable

- Gender: MALE
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone and Calcitriol (Type: EXPERIMENTAL): Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).